Clinical Trial

A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

Study acronym: AmiNA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the ability to slow down or stop the growth of cancer with amivantamab combined with either lazertinib or chemotherapy (carboplatin and pemetrexed) in participants with resectable, epidermal growth factor receptor (EGFR) mutated, Stage II-IIIB non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. NSCLC may occur due to mutations (changes) in many genes, including EGFR.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-07
Trial Details
NCT Number NCT07586202
Lead Sponsor Janssen Research & Development, LLC
Conditions Carcinoma, Non-Small-Cell Lung
Enrollment 68 participants
Start Date 2026-07-17
Primary Completion 2028-03-02 (estimated)
Study Completion 2028-04-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-06